Facilitation of Ca2+-activated K+ channels (IKCa1) by mibefradil in B lymphocytes

Pflugers Archiv European Journal of Physiology

Volumn 456, Issue 3, 2008, Pages 549-560

  Yoo, Hae Young ^a   Zheng, Haifeng ^a   Nam, Joo Hyun ^a   Nguyen, Yen Hoang ^b   Kang, Tong Mook ^b   Earm, Yung E ^a   Kim, Sung Joon ^a  

^a Seoul National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

B cell; Ca2+ activated potassium channel; Channels; Lymphocyte; Membrane potential; Mouse; Potassium channel

Indexed keywords

B LYMPHOCYTE RECEPTOR; CHARYBDOTOXIN; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MIBEFRADIL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; KCNN4 PROTEIN, MOUSE; POTASSIUM CHANNEL BLOCKING AGENT; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL MEMBRANE POTENTIAL; CELL STRAIN HEK293; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ELECTRIC POTENTIAL; EMBRYO; HUMAN; HUMAN CELL; HYPERPOLARIZATION; IC 50; MOLECULAR CLONING; MOUSE; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; ANIMAL; CELL LINE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETIC TRANSFECTION; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; B-LYMPHOCYTES; CALCIUM; CALCIUM CHANNEL BLOCKERS; CELL LINE; CHARYBDOTOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; LYMPHOCYTE ACTIVATION; MEMBRANE POTENTIALS; MEMBRANE TRANSPORT MODULATORS; MIBEFRADIL; MICE; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; TRANSFECTION;

EID: 43149094899     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-007-0438-5     Document Type: Article

References (35)

1. Amigorena S, Choquet D, Teillaud J-L, Korn H, Fridman WH (1990) Ion channel blockers inhibit B cell activation at a precise stage of the G1 phase of the cell cycle. J Immunol 144:2038-2045
2. 2+-activated potassium channel KCNN4. J Biol Chem 279:47681-47687
3. 2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol 48:540-549
4. Blaheta RA, Hailer NP, Brude N, Wittig B, Oppermann E, Leckel K, Harder S, Scholz M, Weber S, Encke A, Markus BH (1998) Novel mode of action of the calcium antagonist mibefradil (Ro40-5967): potent immunosuppression by inhibition of T-cell infiltration through allogeneic endothelium. Immunology 94:213-220
5. 2+ antagonist RO 40-5967 on endothelium dependent responses of isolated arteries. J Cardiovasc Pharmacol 23:869-876
6. + channels as targets for specific immunomodulation. Trends Pharmacol Sci 25:280-289
7. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 54:695-703
8. Enyeart JJ, Xu L, Danthi S, Enyeart JA (2002) An ACTH- and ATP-regulated background K+ channels in adrenocortical cells is TREK-1. J Biol Chem 277:49186-49199
9. Fanger CM, Rauer H, Neben AL, Miller MJ, Wulff H, Rosa JC, Ganellin CR, Chandy KG, Cahalan MD (2001) Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J Biol Chem 276:12249-12256
10. Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, Cahalan MD, Chandy KG (2000) Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 275:37137-37149
11. Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, Maylie J (1997) A human intermeadiate conductance calcium-activated potassium channel. Proc Natl Acad Sci USA 94:11651-11656
12. + channels inhibit human pancreatic cancer cell growth in vitro. Mol Pharmacol 65:630-638
13. + channel of intermediate conductance: a molecular target for novel treatments? Curr Drug Targets 2(4):401-422
14. Karila-Cohen D (1996) Effects of mibefradil on large and small coronary arteries in conscious dogs: role of vascular endothelium. J Cardiovasc Pharmacol 28:271-277
15. Khanna R, Chang MC, Joiner WJ, Kaczmarek LK, Schlichter LC (1999) hSK4/hIK1, a calmodulin-binding KCa channel in human T lymphocytes. Roles in proliferation and volume regulation. J Biol Chem 274:14838-14849
16. + channels in uremic rats. Kidney Int 67(6):2280-2287
17. Koo GC, Blake JT, Talento A, Nguyen M, Lin S, Sirotina A, Shah K, Mulvany K, Hora D, Cunningham P, Wunderler DL, McManus OB, Slaughter R, Bugianesi R, Felix J, Garcia M, Williamson J, Kaczorowski G, Sigal NH, Springer MS, Feeney W (1997) Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol 158:5120-5128
18. Lijnen P, Fagard R, Petrov V (1999) Mibefradil-induced inhibition of proliferation of human peripheral blood mononuclear cells. J Cardiovasc Pharmacol 33:595-604
19. + channels by MgATP in murine immature B lymphocytes. J Biol Chem 279:20643-20654
20. - channels in macrivascular endothelial cells. Br J Pharmacol 121:547-555
21. Nilius B, Droogmans G (2001) Ion channels and their functional role in vascular endothelium. Physiol Rev 81:1415-1459
22. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 13:754-759
23. + channels in breast cancer cells associated with cell cycle progression. Am J Physiol 287:C125-C134
24. Panner A, Wurster RD (2006) T-type calcium channels and tumor proliferation. Cell Calcium 40:253-259
25. + channels in T lymphocytes. Eur Biophys J 34(6):515-529
26. + channel modulators on human prostate cancer cell proliferation. Eur J Pharmacol 471:157-164
27. 2+ dependent. Biochim Biophys Acta 1420:231-240
28. Perchenet L, Clement-Chomienne O (2000) Characterization of mibefradil block of the human heart delayed rectifier hKv1.5. J Pharmacol Exp Ther 295:771-778
29. Reich E-P, Cui L, Yang L, Pugliese-Sivo C, Golovko A, Petro M, Vassileva G, Chu I, Nomeir AA, Zhang L-K, Liang X, Kozlowski JA, Narula SK, Zavodny PJ, Chou C-C (2005) Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmunie encephalomyelitis in mice. Eur J Immunol 35:1027-1036
30. 2+/calmodulin. Nature 410:1120-1124
31. + channels by NS309 (6,7-dichloro-1H- indole-2,3-dione 3-oxime). Biochim Biophys Acta 1665:1-5
32. 2+ channels and drug development. J Pharmacol Sci 99:214-220
33. Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H (2005) International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 57(4):463-472
34. + channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol 173:776-786
35. + current in Bal-17 and WEHI-231 murine B lymphocytes. Korean J Physiol Pharmacol 10:19-24